Ricardo Fernandes
The main objective of our research group is to identify key functional aspects affecting anti-tumor responses by T cells. To do this, we use protein engineering, guided by structural and signaling information, to generate novel molecules that allow us to explore and interrogate key aspects of receptor signaling and T cell function. We are currently focusing our efforts in developing molecules to overcome “inhibitory” signaling by immune checkpoint receptors and to enhance signaling by the T-cell receptor.
Ricardo Fernandes recently joined CAMS Oxford Institute coming from Stanford where he developed novel molecules to effectively shut down signaling by immune receptors such as PD-1.
Recent publications
-
Immune receptor inhibition through enforced phosphatase recruitment
Journal article
Fernandes RA. et al, (2020), Nature, 586, 779 - 784
-
Discovery of surrogate agonists for visceral fat Treg cells that modulate metabolic indices in vivo
Journal article
Fernandes RA. et al, (2020), eLife, 9
-
A Human IgSF Cell-Surface Interactome Reveals a Complex Network of Protein-Protein Interactions
Journal article
Wojtowicz WM. et al, (2020), Cell, 182, 1027 - 1043.e17
-
Opposing T cell responses in experimental autoimmune encephalomyelitis
Journal article
Saligrama N. et al, (2019), Nature, 572, 481 - 487
-
A cell topography-based mechanism for ligand discrimination by the T cell receptor
Journal article
Fernandes RA. et al, (2019), Proceedings of the National Academy of Sciences, 116, 14002 - 14010